Health Law & Business News

Astellas Pharma to Buy Audentes in $3 Billion Gene Therapy Deal

Dec. 2, 2019, 11:31 PM

Astellas Pharma Inc. agreed to buy gene-therapy company Audentes Therapeutics Inc. for about $3 billion, in the latest acquisition by a Japanese drugmaker.

Tokyo-based Astellas will pay $60 a share for San Francisco-based Audentes, according to a statement from the companies. That’s a 110% premium to Audentes’ closing price on Monday. The deal is expected to close in the first quarter of 2020.

The deal will help Astellas expand in the field of gene therapy. It will help accelerate the development of genetics medicines for rare neuromuscular diseases.

“Audentes has developed a robust pipeline of promising product candidates which are...

To read the full article log in. To learn more about a subscription click here.